Law360, New York (October 01, 2009) -- Novo Nordisk Inc. has appealed an injunction forcing the drugmaker to amend key use code in its patent for the diabetes treatment Prandin in litigation seeking to block Caraco Pharmaceutical Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. from manufacturing a generic version.
In a notice of appeal filed Tuesday in the U.S. District Court for the Eastern District of Michigan, Novo challenged the injunction, which requires the drug manufacturer to amend the...


